Subtype
Malignant Pleural Neoplasm
CI-CAN-00001168Explore in graph →
26 active trials4 approved drugs6 evidence items
- NCIt
- C3547
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001168Explore in graph →
Clinical trials
124 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (18)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | terminated | Phase 2 | 35 | Verastem, Inc.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04662645 | Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers | completed | N/A | 68 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06031636 | Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma | unknown | — | 15 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT01486368 | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT02555007 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM(NVB Metro) | completed | Phase 1 | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02436733 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | unknown | Phase 2 | 64 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Nov 7, 2022 | clinicaltrials |
| NCT00652574 | Dasatinib in Resectable Malignant Pleural Mesothelioma | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT00581503 | Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer | withdrawn | — | 0 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT01865045 | Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients | completed | — | 150 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05508555 | Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma | unknown | N/A | 50 | Ain Shams UniversityOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04013334 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | unknown | Phase 2 | 12 | Momotaro-Gene Inc.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04775446 | Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy(MESOIMMUNE) | completed | — | 116 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT05042557 | Real World Study of MPM in China | unknown | — | 500 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | completed | Phase 2 | 42 | Swiss Cancer InstituteOTHER | 2 | Jul 14, 2021 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04713761 | Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02049060 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | completed | Phase 1 / Phase 2 | 31 | Armando Santoro, MDOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03048474 | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma(INITIATE) | completed | Phase 2 | 36 | The Netherlands Cancer InstituteOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | withdrawn | Phase 1 | 0 | Raphael Bueno, MDOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01675765 | Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | completed | Phase 1 | 60 | Aduro Biotech, Inc.INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 40 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03412357 | MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.(MesoTRAP) | completed | N/A | 23 | Papworth Hospital NHS Foundation TrustOTHER_GOV | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02672033 | Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01112293 | Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma | completed | Phase 2 | 14 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02194231 | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)(ATREUS) | completed | Phase 2 | 145 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)(PIPACRegis) | unknown | — | 1,000 | Sabine RhodeOTHER | 13 | Oct 8, 2019 | clinicaltrials |
| NCT01098266 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | completed | Phase 3 | 400 | AGC Biologics S.p.A.INDUSTRY | 12 | Sep 17, 2019 | clinicaltrials |
| NCT01722149 | Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | completed | Early Phase 1 | 4 | University of ZurichOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | terminated | Phase 2 | 10 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT00484276 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma(NGR010) | completed | Phase 2 | 57 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01358084 | Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM(NGR019) | completed | Phase 2 | 137 | AGC Biologics S.p.A.INDUSTRY | 3 | Jan 15, 2019 | clinicaltrials |
| NCT02397928 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | completed | Phase 2 | 82 | NovoCure Ltd.INDUSTRY | 7 | Sep 25, 2018 | clinicaltrials |
| NCT02661659 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02761863 | Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma | unknown | — | 100 | Ain Shams UniversityOTHER | 0 | Feb 23, 2018 | clinicaltrials |
| NCT02269878 | Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma | completed | — | 68 | Ain Shams UniversityOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT03290183 | Confocal Laser Endomicroscopy in Pleural Malignancies | unknown | — | 20 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 21, 2017 | clinicaltrials |
| NCT01355965 | Autologous Redirected RNA Meso-CIR T Cells | completed | Phase 1 | 18 | University of PennsylvaniaOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT02497508 | Nivolumab in Patients With Recurrent Malignant Mesothelioma(NivoMes) | completed | Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT01721018 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.(1716-12) | completed | Phase 1 / Phase 2 | 12 | Virttu Biologics LimitedINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT02369198 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | completed | Phase 1 | 27 | Asbestos Diseases Research FoundationOTHER | 1 | Apr 7, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Feb 20, 2024source: clinicaltrials